Trial Profile
Phase I, Open-Label Study of the Safety and Pharmacokinetics of FG-3019 in Adolescent and Adult Subjects With Steroid-Resistant Focal Segmental Glomerulosclerosis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions
- Sponsors FibroGen
- 05 Sep 2014 New trial record